-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Eastern Sunshine Technology issued an announcement stating that it intends to sell 226 million domestic shares to Guangyao Pharmaceutical, and it intends to sell 226 million H-share "fully tradable" shares to Guangyao's wholly-owned subsidiary, Hong Kong Eastern Sunshine
.
The above two transactions totaled 452 million shares, accounting for approximately 51.
41% of Dongyang Sun Pharmaceuticals' total share capital
.
The transaction price was 3.
723 billion yuan
.
For this transaction, Dongyang said that the company will no longer engage in the production and sales of pharmaceutical-related products; In the future, it will actively expand new businesses in the fields of new energy such as variable frequency energy storage and new energy vehicles
.
It is understood that Dongyang Sunshine actually issued an announcement on August 31 and revealed that it is planning a major asset sale and intends to provide Guangdong Dongyang Sunshine Pharmaceutical Co.
, Ltd.
Co.
, Ltd.
and/or its controlling subsidiaries transferred no more than 51.
41% of the equity of Dongyang Pharmaceutical
.
At that time, the reason for the transfer was that the future performance of Dongyang Pharmaceutical was affected by the epidemic.
Resource advantages such as, channels, etc.
are concentrated in the fields of new electronic materials.
In the future, it is no longer appropriate to invest a large amount of resources in Dongyang Sunshine
.
send letter of inquiry
.
public information, East sunshine East sunshine pharmaceutical is a subsidiary of, has been focused on drug development, production and sale of drugs within China and other services, products cover anti-viral therapeutic areas, endocrine, cardiovascular, etc.
The main products include: Kewei (oseltamivir phosphate) capsules and Kewei granules for the treatment of viral influenza, Ertongshu (benzbromarone tablets) for the treatment of endocrine and metabolic diseases, and Linluo, an anti-infective drug Star (moxifloxacin tablets), Yangzhike (clarithromycin sustained-release tablets), drugs for the treatment of cardiovascular diseases
It is worth noting that although there are 45 drugs on sale, the core product of Dongyang Pharmaceutical is still the flu drug Kewei (oseltamivir phosphate)
.
According to data, the sales of Kewei from 2017 to 2019 were 1.
4 billion yuan, 2.
2 billion yuan, and 5.
9 billion yuan, which brought Dongyang Pharmaceutical's revenue to 1.
602 billion yuan and 2.
51 billion yuan respectively.
, 6.
224 billion yuan; net profits attributable to the parent were 626 million yuan, 901 million yuan, and 1.
907 billion yuan
.
However, in recent years, under the influence of the epidemic, Kewei's sales have begun to decline.
From 20210 to the first half of 2021, it was only 2.
07 billion yuan and 50 million yuan
.
The significant decline in Kewei's sales also brought a significant decline in the overall performance of Dongyang Pharmaceutical.
From 2020 to the first half of 2021, the company's revenue was 2.
348 billion yuan and 202 million yuan, a year-on-year decrease of 62.
27% and 90.
3% respectively
.
In addition to the cause of the epidemic, Dongyang Pharmaceutical's Kewei is actually still facing increasingly fierce market competition
.
In 2017, since the patents related to oseltamivir phosphate compounds expired, 20 domestic companies such as Kelun Pharmaceutical and Suzhou Erye Pharmaceutical have successively submitted oseltamivir listing applications and waited for review
.
Up to now, Borui Medicine's oseltamivir phosphate capsules and CSPC's oseltamivir capsules have been approved one after another
.
In short, from the above, the continuous decline in sales of core products and the increasingly fierce market competition are the main reasons that led Dongyang Technology to sell its shares in Dongyang Pharmaceutical.
How Dongyang Pharmaceutical will develop after the sale depends on the future.
How will it behave
?
.
The above two transactions totaled 452 million shares, accounting for approximately 51.
41% of Dongyang Sun Pharmaceuticals' total share capital
.
The transaction price was 3.
723 billion yuan
.
For this transaction, Dongyang said that the company will no longer engage in the production and sales of pharmaceutical-related products; In the future, it will actively expand new businesses in the fields of new energy such as variable frequency energy storage and new energy vehicles
.
It is understood that Dongyang Sunshine actually issued an announcement on August 31 and revealed that it is planning a major asset sale and intends to provide Guangdong Dongyang Sunshine Pharmaceutical Co.
, Ltd.
Co.
, Ltd.
and/or its controlling subsidiaries transferred no more than 51.
41% of the equity of Dongyang Pharmaceutical
.
At that time, the reason for the transfer was that the future performance of Dongyang Pharmaceutical was affected by the epidemic.
Resource advantages such as, channels, etc.
are concentrated in the fields of new electronic materials.
In the future, it is no longer appropriate to invest a large amount of resources in Dongyang Sunshine
.
send letter of inquiry
.
public information, East sunshine East sunshine pharmaceutical is a subsidiary of, has been focused on drug development, production and sale of drugs within China and other services, products cover anti-viral therapeutic areas, endocrine, cardiovascular, etc.
The main products include: Kewei (oseltamivir phosphate) capsules and Kewei granules for the treatment of viral influenza, Ertongshu (benzbromarone tablets) for the treatment of endocrine and metabolic diseases, and Linluo, an anti-infective drug Star (moxifloxacin tablets), Yangzhike (clarithromycin sustained-release tablets), drugs for the treatment of cardiovascular diseases
It is worth noting that although there are 45 drugs on sale, the core product of Dongyang Pharmaceutical is still the flu drug Kewei (oseltamivir phosphate)
.
According to data, the sales of Kewei from 2017 to 2019 were 1.
4 billion yuan, 2.
2 billion yuan, and 5.
9 billion yuan, which brought Dongyang Pharmaceutical's revenue to 1.
602 billion yuan and 2.
51 billion yuan respectively.
, 6.
224 billion yuan; net profits attributable to the parent were 626 million yuan, 901 million yuan, and 1.
907 billion yuan
.
However, in recent years, under the influence of the epidemic, Kewei's sales have begun to decline.
From 20210 to the first half of 2021, it was only 2.
07 billion yuan and 50 million yuan
.
The significant decline in Kewei's sales also brought a significant decline in the overall performance of Dongyang Pharmaceutical.
From 2020 to the first half of 2021, the company's revenue was 2.
348 billion yuan and 202 million yuan, a year-on-year decrease of 62.
27% and 90.
3% respectively
.
In addition to the cause of the epidemic, Dongyang Pharmaceutical's Kewei is actually still facing increasingly fierce market competition
.
In 2017, since the patents related to oseltamivir phosphate compounds expired, 20 domestic companies such as Kelun Pharmaceutical and Suzhou Erye Pharmaceutical have successively submitted oseltamivir listing applications and waited for review
.
Up to now, Borui Medicine's oseltamivir phosphate capsules and CSPC's oseltamivir capsules have been approved one after another
.
In short, from the above, the continuous decline in sales of core products and the increasingly fierce market competition are the main reasons that led Dongyang Technology to sell its shares in Dongyang Pharmaceutical.
How Dongyang Pharmaceutical will develop after the sale depends on the future.
How will it behave
?
